Arginine depletion as a therapeutic approach for patients with COVID-19

Area of Science:

• Virology
• Immunology
• Biochemistry

Background:

• The COVID-19 pandemic, caused by SARS-CoV-2, necessitates urgent development of effective treatments.
• Current clinical trials primarily investigate direct antivirals or immunomodulation for severe COVID-19.
• Alternative therapeutic strategies, such as amino acid restriction, require further investigation.

Purpose of the Study:

• To explore the rationale for arginine depletion as a potential therapeutic strategy against SARS-CoV-2.
• To evaluate the role of arginine in the viral life cycle and its potential as a therapeutic target.
• To identify potential clinical approaches for inducing arginine depletion for COVID-19 treatment.

Main Methods:

• Review of nonclinical studies on arginine's role in viral replication.
• Exploration of arginine-metabolizing enzymes in clinical development.
• Analysis of the feasibility of inducing a low-arginine environment for therapeutic purposes.

Main Results:

• Arginine is essential for the life cycle of numerous viruses, as indicated by nonclinical studies.
• Arginine depletion presents a promising strategy for disrupting SARS-CoV-2.
• Arginine-metabolizing enzymes are potential candidates for inducing therapeutic arginine deficiency.

Conclusions:

• Arginine depletion represents a viable, yet uninvestigated, therapeutic approach for COVID-19.
• Targeting arginine metabolism could offer a novel treatment modality for SARS-CoV-2 and other viral infections.
• Further clinical investigation into arginine depletion therapies is warranted.